title: Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.
abstract: Triple negative breast cancer (TNBC) is still an incurable disease despite the great scientific effort performed during the last years. The huge heterogeneity of this disease has motivated the evaluation of a great number of therapies against different molecular alterations. In this article, we review the biological bases of this entity and how the known molecular evidence supports the current preclinical and clinical development of new therapies. Special attention will be given to ongoing clinical studies and potential options for future drug combinations.
authors.affiliation: Unidad de Investigación Traslacional, Hospital Universitario de Albacete, Universidad de Castilla La Mancha, Albacete, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Ocana
authors.affiliation: Instituto de Biología Molecular y Celular del Cáncer and CIBERONC. CSIC-Universidad de Salamanca, Salamanca, Spain.
authors.forename: Atanasio
authors.initials: A
authors.lastname: Pandiella
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D063646:Carcinogenesis / Q000187:drug effects*; D000068456:Clinical Studies as Topic / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009857:Oncogenes / Q000187:drug effects*; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: breast cancer; kinases; novel therapies; triple negative breast cancer